Every drug on a pharmacy shelf, every surgical technique a doctor recommends, every vaccine in a public health program, all of it arrived there through the same regulated path: clinical research. Without it, medicine would still operate largely on intuition, anecdote, and tradition. With it, the profession has the evidence it needs to know what works, what is safe, and at what cost.
For Clinical Research Coordinators, understanding the full arc of clinical research, from the laboratory to the label, is not just useful background knowledge. It is the framework that makes every protocol, every consent form, every data entry, and every regulatory requirement make sense. This guide walks through the complete picture, drawing from official definitions and regulatory frameworks established by the FDA, NIH, ICH, and the World Medical Association.
What Is Clinical Research? The Official Definition
The National Institutes of Health defines a clinical trial as a research study in which one or more human subjects are prospectively assigned to one or more interventions to evaluate the effects of those interventions on health-related biomedical or behavioral outcomes. This definition, revised by NIH in 2014 to sharpen the distinction between clinical trials and other forms of human research, is the standard used by all NIH-funded investigators and most regulatory agencies. It is available in full on the NIH Grants and Funding site.
The term "clinical research" is broader than "clinical trial." Clinical research includes any research that involves human participants, including observational studies that simply follow patients over time without assigning any intervention, behavioral research, epidemiological studies, and the clinical trials that test specific interventions. A clinical trial is therefore a type of clinical research, specifically one where participants are assigned to receive something (a drug, a device, a behavioral change, a placebo) and the effects are measured.
The NIH's public overview of clinical research notes that the idea for a clinical trial often starts in the laboratory. After researchers test new treatments in animals, the most promising candidates are moved into clinical trials — progressing through a series of phases designed to generate increasingly robust evidence about safety and effectiveness.
Clinical Research vs. Basic Research: What Is the Difference?
Basic research, sometimes called bench research or laboratory research, investigates fundamental biological and chemical processes without an immediate clinical application in mind. It asks questions like: How does this protein function? What happens to a cell when this gene is switched off? Basic research generates the discoveries that clinical research then takes forward into human testing.
Clinical research is the translational step. It takes findings from the bench and tests them in human beings under controlled, ethical, and regulated conditions. The two are not in competition. They are sequential and interdependent. No clinical trial can begin without preclinical data establishing a biological rationale and initial safety profile. No basic discovery reaches patients without clinical research that confirms its safety and efficacy at scale.
The comprehensive review of clinical trials published in PMC (peer-reviewed through the NIH's National Library of Medicine) distinguishes between the two study types this way: non-interventional studies observe what happens in nature or in existing clinical practice, while interventional studies, clinical trials, deliberately assign participants to treatments and measure the outcomes. Most of the regulatory infrastructure governing clinical research exists specifically because of this intervention: when researchers deliberately expose humans to experimental treatments, strict oversight is required to protect them.
Before Human Trials: Preclinical Research
Before any new drug or treatment can be tested in humans, it must undergo preclinical research — laboratory and animal studies designed to establish whether the product is reasonably safe to administer to human subjects. This is not optional; it is a regulatory prerequisite. The FDA's guidance on the IND application process states that during a new drug's early preclinical development, the sponsor's primary goal is to determine if the product is reasonably safe for initial use in humans and whether it exhibits pharmacological activity that justifies moving forward.
Preclinical data that must be assembled before an IND can be filed includes animal pharmacology and toxicology studies demonstrating reasonable safety for initial human use; manufacturing information confirming that the sponsor can produce consistent, stable batches of the investigational product; and proposed clinical protocols with justification that the initial phase trials will not expose subjects to unreasonable risk.
The preclinical phase may take years. Many compounds that show initial promise fail here — either because animal studies reveal unacceptable toxicity, or because the biological mechanism does not translate as expected into a living system. This is an essential filter. Everything that reaches a human participant in a Phase I trial has already survived a rigorous, regulated evaluation process.
The IND Application: FDA Authorization to Proceed
Before a sponsor can administer an investigational drug to human subjects in the United States, or ship it across state lines for that purpose, they must file an Investigational New Drug (IND) application with the FDA. Current Federal law requires that a drug be the subject of an approved marketing application before it is transported or distributed across state lines. Because sponsors need to ship investigational product to clinical investigators in multiple states, the IND provides the technical exemption from that requirement.
The IND contains three major categories of information: preclinical data (animal pharmacology, toxicology, and any prior human experience with the compound); manufacturing information (composition, stability, controls, and quality of the product); and clinical protocols describing the proposed studies in sufficient detail for FDA to assess whether subjects will face unreasonable risks.
Once the IND is submitted, the sponsor must wait 30 calendar days before initiating any clinical trials. During that window, the FDA reviews the application for safety to confirm that participants will not be exposed to unreasonable risk. If FDA does not place a clinical hold on the application within that 30-day period, the sponsor may proceed. Investigators working at sites on an IND study are operating under that authorization, and their compliance with the approved protocol is both an ethical obligation and a legal one under 21 CFR Part 312.
The Four Phases of Clinical Trials
Clinical trials are organized into phases, each designed to answer a progressively more complex set of questions about a treatment. Phase definitions used in the United States are established by the FDA and are described in detail in the NIH's clinical research overview and the NIH's glossary of clinical research terms.
Phase I — Safety and Dosage
Phase I trials are the first testing in humans, typically involving 20 to 80 participants, often healthy volunteers. The primary purpose is to evaluate the drug's safety profile, identify side effects, and determine the maximum tolerated dose and how the drug is absorbed, distributed, metabolized, and eliminated by the body. Phase I trials are not designed to establish whether the treatment works. They are designed to establish whether it is safe enough to study further.
Phase II — Efficacy and Further Safety
Phase II trials expand testing to a larger group, typically 100 to 300 participants, who have the condition the treatment is intended to address. The primary questions shift to efficacy: does the treatment actually produce the intended biological or clinical effect? Phase II also continues to evaluate safety and begins to explore optimal dosing in the target patient population. A Phase II failure is common; many treatments that showed safety in Phase I do not demonstrate sufficient efficacy at this stage to justify the cost and risk of Phase III.
Phase III — Confirmation and Comparison
Phase III trials are large-scale, typically enrolling 1,000 to 3,000 or more participants across multiple sites, often internationally. Their purpose is to confirm efficacy, monitor side effects at scale, compare the new treatment to existing standard-of-care treatments, and collect the comprehensive safety and effectiveness data that will support a New Drug Application. Phase III trials are the primary basis for FDA marketing approval decisions and are the most resource-intensive studies. CRCs working on Phase III trials are operating at the center of the evidence base that will eventually determine whether a new treatment reaches patients worldwide.
Phase IV — Post-Marketing Surveillance
Phase IV trials occur after a drug has been approved by the FDA and is available to the public. They track the drug's safety, benefits, and optimal use in the broader general population — a population that is far more diverse in age, health status, and co-medications than the populations enrolled in Phase III. Phase IV research may identify rare adverse effects that did not appear in earlier trials due to smaller sample sizes, or may evaluate the drug's performance in populations that were underrepresented in pre-approval studies.
Types of Clinical Trials Beyond Drug Studies
Not all clinical trials test drugs. The NHLBI's overview of clinical trial types describes several categories: behavioral trials evaluate ways to promote health behavior changes; diagnostic trials study or compare tests or procedures for detecting conditions; prevention trials look for better ways to prevent disease in people who have not yet developed it; quality-of-life trials explore ways to improve comfort for people with chronic conditions; and screening trials test new methods for detecting diseases. CRCs may encounter any of these trial types depending on their site's specialty and sponsor relationships.
The NDA: From Trial Data to Marketing Approval
When a sponsor believes that the data accumulated across Phase I, II, and III trials provide sufficient evidence of a drug's safety and effectiveness, they submit a New Drug Application (NDA) to the FDA. The NDA is the formal vehicle through which a drug sponsor proposes that the FDA approve a new pharmaceutical for sale and marketing in the United States. The data gathered during animal studies and human clinical trials of the Investigational New Drug become part of the NDA.
The NDA review process addresses three key questions: Is the drug safe and effective in its proposed use, and do its benefits outweigh its risks? Is the proposed labeling appropriate? Are the manufacturing methods and quality controls adequate to ensure the drug's identity, strength, quality, and purity? The FDA has 60 days after receiving an NDA to decide whether to file it for review. Once filed, a review team evaluates the full body of clinical evidence before rendering an approval decision.
The path from IND submission to NDA approval typically takes years and involves thousands of participants across dozens or hundreds of clinical sites. Every data point in that NDA was generated at a site like yours, by a team like yours, following a protocol like the ones you work under every day. The regulatory rigor applied at the site level — accurate source documentation, compliant consent processes, disciplined IP accountability — is what makes that evidence credible enough to support a marketing decision that will affect patients for decades.
Ethics and Oversight: The Framework That Protects Participants
The ethical framework governing clinical research was forged through some of medicine's darkest chapters. The Declaration of Helsinki, first adopted by the World Medical Association in 1964 and most recently revised in October 2024, is the foundational international statement of ethical principles for medical research involving human participants. It establishes that the primary purpose of medical research is to generate knowledge, but that this goal can never override the rights, safety, and welfare of the individuals who participate. The Declaration's principles hold that every research protocol must be approved by an independent research ethics committee before the study begins, that participation must be voluntary and based on informed consent, and that the wellbeing of individual participants takes precedence over the interests of science and society.
In the United States, these principles are operationalized through two parallel regulatory frameworks. The first is the FDA's regulations at 21 CFR Part 50, which govern the protection of human subjects and establish the requirements for legally effective informed consent in FDA-regulated research. The second is the Department of Health and Human Services' regulations at 45 CFR Part 46, the Common Rule, which apply to federally funded research. For most clinical trials involving FDA-regulated products that are also federally funded, both sets of regulations apply simultaneously.
The Role of the Institutional Review Board
The Institutional Review Board (IRB) — or Independent Ethics Committee (IEC) outside the United States — is the independent body responsible for reviewing and approving clinical research protocols before any participants are enrolled. The NIH describes IRBs as governing bodies that approve protocols and are responsible for ensuring participant safety throughout the study. An IRB must review and approve the protocol, all amendments to the protocol, and all participant-facing materials including the informed consent form before they can be used. Studies may not continue past an IRB approval's expiration date — a lapse requires all study activities to stop immediately.
For CRCs, maintaining an unbroken chain of IRB approval is one of the most critical site operations responsibilities. A lapsed approval is not a technical oversight: it is a serious GCP violation that means any study activity conducted after the expiration date was conducted without ethical authorization.
Informed Consent: The Foundation of Participant Autonomy
Informed consent is both a regulatory requirement and an ethical cornerstone. The FDA's Informed Consent Guidance for IRBs, Clinical Investigators, and Sponsors, finalized in August 2023, establishes that the informed consent process begins before a participant ever signs a form, with the advertisements used to recruit them, and continues throughout the duration of their participation, requiring investigators to share any significant new safety information that emerges during the study.
Informed consent is not a signature. It is a process of communication through which a potential participant receives accurate, complete information about the study's purpose, procedures, risks, benefits, and alternatives, and has a genuine opportunity to ask questions and decide voluntarily whether to participate. 21 CFR Part 50 specifies the eight basic elements that must be present in every informed consent document for FDA-regulated research, including a description of the study's purpose, a description of foreseeable risks, a description of reasonably expected benefits, and a disclosure of available alternative treatments.
Good Clinical Practice: The International Quality Standard
The regulatory and ethical frameworks described above are harmonized across international jurisdictions through Good Clinical Practice (GCP), the international standard for designing, conducting, recording, and reporting clinical trials involving human participants. The current GCP standard is ICH E6(R3), finalized by the International Council for Harmonisation on January 6, 2025, and recognized by regulatory authorities including the FDA and EMA.
GCP governs every aspect of clinical trial conduct: the qualifications required of investigators and staff, the standards for source documentation, the requirements for informed consent, the oversight obligations of sponsors, and the essential documents that must be maintained throughout a trial's lifecycle. Compliance with GCP is what allows clinical trial data generated in one country to be accepted by regulatory authorities in another: it is the common language of clinical research quality worldwide.
For a CRC, GCP is not an abstract standard. It is the day-to-day operating framework. The delegation log, the training documentation, the source-to-CRF data verification, the IP accountability records, the IRB correspondence, all of it exists because GCP requires it. Understanding why each element exists, rather than simply following instructions to produce it, is what distinguishes an exceptional CRC from an adequate one.
The CRC's Role in the Clinical Research Continuum
The Clinical Research Coordinator occupies a position that is easy to underestimate from the outside, and nearly impossible to underestimate once you understand the full arc of drug development described in this guide. The CRC is the person on the ground at the site who makes every phase of a clinical trial operationally possible. Without competent, compliant site coordinators, Phase III trials cannot enroll. Without enrolled Phase III participants, the NDA cannot be filed. Without an NDA, a treatment that works cannot reach patients.
The data quality that CRCs maintain — accurate, contemporaneous, complete, and attributable source documentation — is the literal foundation of the evidence base that the FDA reviews when it decides whether to approve a new treatment. When the NDA review team opens the clinical data file, the source documents behind it were created by CRCs following protocols, completing visit windows, verifying eligibility criteria, and documenting adverse events with precision.
Understanding clinical research from discovery to approval gives every task in a CRC's day a context and a purpose. The protocol deviation that must be reported, the consent that must be re-obtained, the temperature excursion that cannot be ignored, these are not bureaucratic inconveniences. They are the guardrails of a process designed to generate evidence that is trustworthy enough to shape how medicine is practiced for generations of patients who will never know your name.
Verified References & Primary Sources
- NIH — Definition of a Clinical Trial — Official NIH definition, revised 2014. The standard used by NIH-funded investigators and most regulatory agencies.
- NIH — Clinical Research Trials: The Basics — NIH's public overview of how clinical trials work, including phase definitions and participant protections.
- NIH — Glossary of Common Clinical Research Terms — Official NIH definitions for key terms including phase descriptions, randomization, protocol, and principal investigator.
- NHLBI — How Clinical Trials Work — National Heart, Lung, and Blood Institute overview of trial types, phases, and participant protections.
- FDA — Investigational New Drug (IND) Application — FDA overview of the IND process, including preclinical requirements, the 30-day review window, and the role of the IND in enabling interstate shipment of investigational product.
- FDA — New Drug Application (NDA) — FDA explanation of the NDA: what it contains, the three key questions it addresses, and the review process.
- FDA — Drug Review Process — FDA description of the NDA review process, including the 60-day filing decision, the review team evaluation, and accelerated approval pathways.
- 21 CFR Part 312 — Investigational New Drug Application — The federal regulations governing IND applications, investigator responsibilities, and recordkeeping requirements.
- 21 CFR Part 50 — Protection of Human Subjects — FDA regulations governing informed consent requirements, including the eight required basic elements of informed consent.
- FDA — Informed Consent Guidance for IRBs, Clinical Investigators, and Sponsors — Finalized August 2023. Comprehensive guidance on the informed consent process, delegation of consent, and ongoing consent obligations.
- World Medical Association — Declaration of Helsinki — Revised October 2024. The foundational international statement of ethical principles for medical research involving human participants.
- ICH E6(R3) — Good Clinical Practice Guideline — Finalized January 6, 2025. The international standard governing the design, conduct, recording, and reporting of clinical trials involving human participants.
- PMC — Clinical Trials and Clinical Research: A Comprehensive Review — Peer-reviewed article via NIH National Library of Medicine covering trial phases, designs, and the distinction between interventional and observational research.